Introduction
Candidiasis, one of the most frequent fungal diseases in humans, is generally caused by Candida albicans [1] . This fungus is a commensal organism of the oro-gastrointestinal tract and the vulvovaginal cavity. However, in some individuals, C. albicans causes disease, either by infecting mucosal and epidermal surfaces (mucocutaneous candidiasis, which is typically chronic) or, more rarely, by disseminating in the blood (systemic candidiasis, which is typically acute) [2, 3] . Patients with inherited or acquired disorders of granulocytes usually present systemic candidiasis, whereas patients with inherited or acquired disorders of T lymphocytes develop chronic mucocutaneous candidiasis (CMC) [3] [4] [5] [4, 5] . Various alterations of the internal (e.g. a central line) or peripheral (e.g. xerostomy) milieu may also predispose to invasive or mucocutaneous CMC. CMC is highly heterogeneous clinically, with recurrent and/or persistent infections of the upper gastro-intestinal mucosa, skin, and nails with C. albicans, which may respond poorly to anti-fungal treatment or relapse upon discontinuation of treatment [2, 6] . The mucocutaneous lesions are not themselves lifethreatening, but they have been associated with intracranial aneurisms in several patients with CMC, at least in patients with isolated, unexplained CMC [7] [8] [9] .
CMC is usually associated with many other, frequently more severe infections, particularly in patients with broad and profound inherited or acquired T-cell immunodeficiencies.
Oropharyngeal infections with Candida species are commonly found in HIV-infected individuals [10, 11] . Persistent oral candidiasis and other mucocutaneous fungal infections are also often observed in infants with severe combined immunodeficiency (SCID) [12- 16]{Casanova, 2007 #495}. T cells therefore play a critical role in protective immunity against mucocutaneous C. albicans infections [14, 15, 17] [2, 27, 28] . Abnormalities of T-cell immunity to C. albicans have occasionally been reported in these patients, but no genetic etiology has yet been identified [2, 6, [29] [30] [31] [32] [33] [34] .
In recent years, the molecular pathogenesis of CMC in patients with primary immunodeficiencies has begun to be deciphered{Conti, 2010 #513}. This process has been facilitated by the development of a mouse models for CMC [35] and the discovery of IL-17 cytokines: IL-17A, IL-17F, IL-22 and IL-26 in humans [36, 37] . Mouse IL-17 cytokines are essential for mucocutaneous immunity to C. albicans [5, 38] . However, these cytokines are also essential for protective immunity to many other pathogens, including Gram-positive and Gram-negative bacteria, such as Staphylococcus, Klebsiella and Salmonella, in various tissues, including the respiratory and gastro-intestinal tracts [39] [40] [41] [42] [43] . Patients with mutations in STAT3 have been shown to lack IL-17-producing circulating T cells [44] [45] [46] 
AD-HIES syndrome
Cutaneous and pulmonary staphylococcal diseases affect most, if not all patients with AD-HIES, but CMC is the second most frequent presentation, affecting about 80% of AD-HIES patients [18, [49] [50] [51] [18, 49, 51] . CMC generally manifests as oral thrush, onychomycosis, and/or vaginal candidiasis, cases of median rhomboid glossitis have also been reported [51] . Dermatophytosis has also been described in some patients. In 2007, dominant-negative mutations in the STAT3 gene, encoding signal transducer and activator of transcription 3, were found to be responsible for AD-HIES [19, 20] . STAT3 regulates multiple cytokine signaling pathways, including IL-6, IL-21, and IL-23, which are involved in the development of IL-17-producing T cells in mice [36, 52, 53] . Several groups investigated the presence of IL-17-producing T cells in STAT3-deficient patients with AD-HIES, based on the findings that mouse IL-17-producing T cells play a role in immunity to both systemic and mucosal C. albicans infection [38, 54, 55] , these T cells are involved in skin and mucosal host defense [56, 57] , and mouse STAT3-deficient CD4 + T cells are unable to differentiate into IL-17-producing T cells [58] . In From2008 onwards, threefive studies documented an almost complete lack of circulating IL-17-producing T cells in patients heterozygous for STAT3 mutations, as assessed ex vivo [44] [45] [46] [44] [45] [46] . This lack of differentiation was associated with the impaired induction of RORγt mRNA upon stimulation of the patients' CD4 + T cells, suggesting an intrinsic T-cell defect [44, 45] . Two studiesThree studies reported a concomitant decrease in IL-22 production [45, 46] {Minegishi, 2009 #401;
Renner, 2008 #511}, whereas a third fourth did not [44] . The other IL-17 cytokines, IL-17F
and IL-26, were not studied. The strong impairment of T-cell differentiation seemed to be specific to IL-17-producing T cells, although other lymphokines (such as IL-2 and IFN-γ)
were also found to be affected, but to a lesser extent [44] [45] [46] . The proportion of circulating 
IL-12p40 and IL-12Rβ1 deficiencies
Another study showed that IL-12p40-and IL-12Rβ1-deficient patients, displaying a lack of production and of response, respectively, to both IL-12 and IL-23 have smaller proportions of circulating IL-17-producing T cells than normal individuals, but that this deficiency is much milder than that in patients with AD-HIES [46] . IFN-γ responses [62] . The lack of overt staphylococcal disease in IL-12p40-and IL-12Rβ1-deficient patients, by contrast to the situation observed in AD-HIES patients, may be due to the presence of a sufficiently high proportion of IL-17-producing T cells in IL-12p40-and IL-12Rβ1-deficient patients. The almost complete lack of IL-17-producing T cells in patients heterozygous for STAT3 may therefore account for the susceptibility of these patients to both staphylococcal disease and CMC, the two key infections in such patients. This susceptibility may involved impairment of the recruitment of granulocytes to infected tissues and their activation, and of the induction of antimicrobial peptides in epithelial cells [42] . Consistent with this hypothesis, epithelial cells in the skin and lungs, the organs most frequently affected by staphylococcal disease and CMC in STAT3-deficient patients, have been shown specifically to require IL-17 stimulation for the induction of antimicrobial target genes [42, 66] .
CARD9 deficiency
Caspase recruitment domain-containing protein 9 (CARD9) is an adaptor acting downstream from C-type lectin receptors, such as Dectin-1 [67, 68] . Dectin-1 recruits and activates the spleen tyrosine kinase SYK [69] . The Dectin-1/SYK complex then engages CARD9, promoting pro-inflammatory cytokine production by dendritic cells, thereby inducing the differentiation of T cells into IL-17-producing T cells [70] . Card9-deficient mice are susceptible to systemic C. albicans infection [68] and fail to mount a Candida-specific IL-17-producing T-cell response [70] . In humans, autosomal recessive CARD9 deficiency (Q295X 
DECTIN-1 deficiency?
Dectin-1, a C-type lectin cell-surface receptor expressed, in particular, by myeloid and epithelial cells, serves as a receptor for β-glucans, a major component of the yeast cell wall [79] . C. albicans recognition by Dectin-1 induces, via SYK and CARD9, the production of pro-inflammatory cytokines, thereby promoting the differentiation of naive T cells into cells producing IL-17 cytokines [70] . Dectin-1-deficient mice were shown to be susceptible to systemic C. albicans infection in one study [80] but not in another [81] . 
APECED/APS-I syndrome
APS-I/APECED is a rare autosomal recessive syndrome characterized by multiple autoimmune polyendocrinopathies, such as hypoparathyroidism and adrenal failure [82, 83] .
The genetic etiology of APS-I was identified in 1997, with mutations in the autoimmune regulator (AIRE)-encoding gene [84, 85] . AIRE governs a T-cell tolerance pathway, by inducing the production, in the thymus and peripheral lymphoid organs, of transcripts encoding proteins normally present in various peripheral tissues [83, 86] Auto-Abs against all other cytokines tested, including those known to cause distinct clinical syndromes, such as IL-6, IFN-γ, and GM-CSF [93] [94] [95] [96] [97] , were undetectable. Remarkably, two patients with thymoma and CMC were found to have auto-Abs against IL-17 cytokines [48] , unlike patients with thymoma without CMC, suggesting that the auto-Abs against IL-17 cytokines were responsible for the CMC. Moreover, auto-Abs were found in some patients with APS-I but without CMC, and even before the onset of CMC in some cases, suggesting that these auto-Abs are probably a cause rather than an effect of CMC. However, although correlative [98] , the high titers of neutralizing auto-Abs against IL-17 cytokines in APS-I patients are probably sufficient to account for CMC. Clearly, these findings pave the way for the treatment of CMC in these patients with B cell-depleting, CD20-specific monoclonal Abs.
Immunosuppression was used reluctantly in APS-I patients, in part because of the fear to aggravate CMC. The discovery that CMC has an auto-immune basis suggests that 
Conclusion
Three human inborn errors of immunity (AD-HIES, CARD9 deficiency, and APS-1) are associated with CMC as a key infectious phenotype. Patients with AD-HIES are also vulnerable to other infections, including staphylococcal disease in particular, and patients with CARD9 deficiency are vulnerable to systemic candidiasis, whereas CMC seems to be the only infection of note in patients with APS-I. In patients with these three disorders, the pathogenesis of CMC seems to involve impaired IL-17 immunity, involving IL-17A, IL-17F, and/or IL-22. This conclusion is strongly correlative, but further human genetic studies are required to document the collective and individual impact of IL-17 cytokines in host defense.
The investigation of patients with isolated CMC, with no other autoimmune or infectious phenotype, may be rewarding [34] . No genetic etiology has yet been identified in patients with isolated CMC. Definitive proof of the role of IL-17 cytokines in immunity to C. albicans infection must await the identification of patients with isolated CMC and inherited disorders specifically affecting IL-17 immunity [99, 100] .
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